More complete nonsense from Josepth Mercola --- a clown who has pushed endless Covid misinformation. LOL.
When you constantly post sources that constantly push complete misinformation then it is not worth discussing the latest nonsense they are pushing. If you want to discuss facts then you can post facts from reputable mainstream sources and studies -- otherwise you are just re-posting fabricated crap.
Risk of myopericarditis from Covid vaccine 'no different' from other jabs, say experts https://www.express.co.uk/life-styl...-myopericarditis-risk-no-different-other-jabs
Third doses of COVID-19 vaccines not associated with increase in reports of serious adverse events: study https://www.ctvnews.ca/health/coron...rts-of-serious-adverse-events-study-1.5864890 A new study looking at data concerning around 48,000 people in the U.S. has found that third doses of mRNA vaccine, such as those from Pfizer or Moderna, are safe and did not cause any increase in reporting of serious adverse events. The study, published in the journal JAMA Network Open on Thursday, found that third doses did not result in an increase in severe adverse events compared to earlier doses, but did come with an increase in low-severity adverse events, such as fatigue and nausea. “Results from this cohort study suggest that a third dose of the same type of vaccination after a BNT162b2 or mRNA-1273 primary series is associated with safe outcomes,” the study stated. The COVID-19 vaccines produced by Pfizer-BioNTech and Moderna were originally designed as two-dose regimes, supported by extensive clinical trials. As studies showed evidence of waning vaccine immunity, health experts began to suggest booster shots, which were found to be safe and effective. But there is still less data on these third doses than on the first and second doses, a gap in knowledge that researchers were hoping to close in this new study. Researchers accessed electronic medical records provided by 47,999 adults within the Mayo Clinic Enterprise, a non-profit hospital system in the U.S., all of whom who were vaccinated with three doses of the same mRNA COVID-19 vaccines between December 2020 and Oct. 17, 2021. Around 38,000 participants received the Pfizer-BioNtech vaccine for their three doses, while around 9,900 received the Moderna vaccine. There were more than twice the amount of immunosuppressed individuals in the group who received Moderna than in the group that received Pfizer. No adverse events specific to a certain brand was reported in the study. The most common adverse events after receiving the third dose were fatigue, the temporary swelling of lymph nodes, nausea and headache, with these symptoms reported by around two to five per cent of participants. Less than two per cent of participants reported other common side effects such as joint pain, muscle aches, diarrhea and fever. These numbers, while still small, represented a significant increase in how often these same participants had reported these side effects after their first or second dose. After the third dose, two patients had anaphylaxis, four patients had a swelling of tissue around the heart called pericarditis and one patient reported myocarditis, meaning only 0.01 per cent of participants reported one of these serious adverse events. “Reporting of severe adverse events was rare after the third dose and was not significantly increased compared with the frequency of reporting after the second dose,” the study stated. Researchers also monitored emergency department visits for participants within two days of receiving each dose of the vaccine, and found that there was an increase in emergency department visits after a third dose of the Pfizer vaccine compared to the second. Overall, 0.29 per cent of people visited the emergency department after a third dose versus 0.2 per cent after the second dose. There was no difference in ER visits for different doses for those receiving Moderna. The overall results indicate that third doses are indeed safe, as they don’t come with an increase in severe adverse events, researchers said. They added that third doses had a better safety profile in this study than receiving a single dose did. “Individuals who received exactly [one] dose of an mRNA-based COVID-19 vaccine had greater increases in incidence of adverse events after dose [one], compared with baseline, than what was observed in the [three]-dose cohort,” the study stated. Researchers noted that there are limitations to the study, such as the fact that people receiving mixed brands were not included and that those receiving third doses are more likely to be older and immunosuppressed, thus potentially having a reduced immune reaction to the vaccine that could show less adverse effects. Further studies into third doses will hopefully be able to flesh out more on the safety profile of mixing vaccine brands to further narrow down how frequent rare adverse events are, the study stated.
This is not surprising considering the J&J Covid vaccine is less effective than mRNA vaccines and J&J had issues with blood clots. Along with large stockpiles of J&J which are not being used and other countries will not accept. J&J suspends sales forecast for COVID vaccine, cuts profit view https://www.reuters.com/business/jo...s-sales-forecast-covid-19-vaccine-2022-04-19/ Johnson & Johnson (JNJ.N) on Tuesday cut its full-year profit expectation and suspended sales forecast for its COVID-19 vaccine after having earlier predicted as much as $3.5 billion in sales from the shot. The world's largest healthcare conglomerate cited uncertain demand and supply surplus of rival shots that have fared much better than its single-dose vaccine for cancelling the forecast. The vaccine, which is sold at a "not-for-profit" price, brought in $457 million in the first quarter. Its sales last year had underperformed rival mRNA shots also due to manufacturing bottlenecks and safety concerns. Pfizer Inc (PFE.N) has forecast $32 billion in 2022 sales from its COVID vaccine developed with BioNTech , while Moderna (MRNA.O) has forecast $21 billion. J&J said it now expects full-year adjusted profit forecast to be between $10.15 and $10.35 per share, lower than the prior forecast of $10.40 to $10.60. Overall sales of $23.43 billion in the first quarter missed Refinitiv estimates of $23.61 billion. "The slight miss was really around the COVID-19 vaccine and quite frankly it met our internal expectations. There was just a disconnect into how the Street assumed it was going to play out over the year," Chief Financial Officer Joseph Wolk told CNBC. Last year, production at the Maryland plant of its contract manufacturer Emergent BioSolutions (EBS.N) was halted by the U.S. Food and Drug Administration last as an accidental mix-up of ingredients ruined about 15 million vaccine doses. The New York Times had reported in February that J&J shut down the only plant making usable batches of its COVID-19 vaccine late last year. Excluding items, J&J earned $2.67 per share, beating market expectation of $2.56 per share.
Several countries have now developed their own vaccines and sharing the vaccines with other countries too. Simply, there's no longer a monopoly by a few vaccine makers...much more competition, more people satisfy (incorrectly) that Covid is over and they do not need additional vaccinations. In addition, more anti-viral therapeutic treatments are available that encourage people to ignore vaccinations while having the therapeutic treatments as a backup plan if they develop a severe Covid infection. Thus, the weaker vaccine makers will see their profit forecast lowered as expected. Regardless, J&J has many other pharmaceutical products not related to Covid. Thus, they're a powerhouse pharmaceutical company. More importantly, we humans are a nasty species when viruses/bacteria show up...we love allowing things to escalate into the worst-case scenario...Pandemics. wrbtrader